This article presents methods of effective treatment of primary metastatic nasopharyngeal carcinoma, both causative and symptomatic, taking into account possible available treatment therapies (chemotherapy, targeted therapy, radiotherapy), and includes a case report. The applied treatment allowed for satisfactory control of the disease and much higher overall survival than expected -the patient survived for 53 months from the initial diagnosis and 41 months from being diagnosed with metastatic carcinoma.
A
www.oncoreview.pl IntroductIon nasopharyngeal carcinoma (nPc) is a rare disease in Poland compared to the endemic areas of east asia, north africa, and the areas of the Mediterranean Basin. The frequency of its occurrence in caucasians is 0.2/100,000. in Poland, around 150 new cases are reported annually [1, 2] .
according to WHo, there are three subtypes of nPc:
• type 1 -squamous cell keratinised carcinoma
• type 2 -differentiated non-keratinised carcinoma
• type 3 -non-differentiated non-keratinised carcinoma.
initial development of nasopharyngeal carcinoma is not accompanied by any symptoms, and no specific symptoms are present at early stages of tumour growth. The time which elapses from the first clinical symptoms to a diagnosis is on average [8] [9] [10] months. The most common clinical symptom in most patients is cervical lymphadenopathy [3] . epstein-Barr virus (eBV) plays the most important role in the pathophysiology of type ii and iii nasopharyngeal carcinoma [4, 5] . Type i is the most common in regions with low morbidity [6] .
nPc is biologically different from other squamous cell carcinomas of the head and neck. non-differentiated carcinoma is diagnosed in 95% of patients with nPc, and is characterised by frequent metastases to regional lymph nodes, distant metastases to the bones, and, the least frequently, to the lung [7, 8] .
in the case of early and regionally advanced carcinomas, a first-line therapy is radiotherapy or, more frequently, chemotherapy. a basic therapy used in the treatment of metastatic nasopharyngeal carcinoma is chemotherapy. clinical studies show that the cisplatinum based treatment results in response of 50-70%, but advantages are short-term, lasting usually 6-9 months [9] . in europe, relative yearly survival in patients diagnosed with nPc is 76%, and a 5-year survival rate is 50% [10, 11] . Distant metastases and regional recurrence are the most common causes of deaths in patients with nPc [12] . Metastases occur most frequently in the bones, and frequently in the lungs and in the liver.
The median survival in patients with metastatic nPc is 8 months [13] . This work presents a case of a man diagnosed with type iii nasopharyngeal carcinoma, originally metastatic, who survived 53 months due to the applied therapy. Positive prognostic factors in the case of nPc are an age below 44 years upon diagnosis, good response to a radical therapy, no relapse for more than 6 months, and no regional recurrence from the end of radical treatment [12, 13] . all these factors occurred in our patient.
nPc is a radiosensitive cancer, and, therefore, radiotherapy is applied as a standard procedure for all early and locally advanced carcinomas. in the case of rare carcinomas, such as nPc, the best treatment regime is hard to develop. a first-line therapy in the majority of patients is chemoradiotherapy combined with cisplatinum. in the case of patients with the first stage of cancer development, radiotherapy alone can be administered. for the second stage, chemotherapy is recommended to avoid distant metastases, however, randomized studies into the subject are absent [19, 20] . limited recurrence is potentially curable, and the main problem is the choice of an appropriate therapeutic option from radiotherapy, brachytherapy, surgical resection, and the possibility of adding systemic treatment. in the case of metastatic nPc (stage iV c), only palliative therapy is an option. Treatment based on platinum derivatives is usually used as a first-line therapy since cisplatinum was proved to be the most effective drug [20] . Randomised clinical studies have shown that the most effective form of systemic treatment is a polytherapy with Pf regNasopharyngeal carcinoma -treatment possibilities in patients with primary metastatic carcinoma M. Kowalczyk, M. Piątek, D. Imielska-Zdunek, A. Derra, A. Zemła, A. Boratyn-Nowicka
www.oncoreview.pl imen being a recommended combination [19] . other cytostatic drugs with proven effectiveness are paclitaxel, docetaxel, gemcitabine, irinotecan, doxorubicin, and oxaliplatin [9, [19] [20] [21] [22] . Most commonly, the treatment includes two lines of palliative chemotherapy. another drug with anti-cancer activity against squamous cell carcinomas located in the head and neck is cetuximab.
The drug is an igg1 monoclonal antibody against the epidermal growth factor receptor (egfR), able to destroy it, not commonly used in the treatment of nPc [23] . egfR is present in the majority of human cancers of epithelial origin, and is associated with more aggressive development, resistance to treatment, and a worse prognosis [24] . egfR is present in over 85% of nPc cases [25] . Biological therapy is used more and more frequently in the treatment of non-keratinizing nPc, particularly in the case of failures or recurrences, although there are no randomized clinical studies proving the effectiveness of such procedure [26] . The initial radical treatment regimen applied in the case of the above patient was compliant with recommendations. The 2 × Pf induction chemotherapy and chemoradiotherapy brought about the desired effect resulting in full regression. upon observing distant metastases, due to their location (l3 vertebra), radiotherapy was applied which was then followed by palliative chemotherapy (6 × Pf). even though no standard procedure was applied after progression subsequent to the first line of palliative chemotherapy, it was resolved to continue the therapy due to the very good overall condition of the patient, and good response to the treatment.
The patient in question was treated with 5 lines of palliative chemotherapy and one line of immunochemotherapy. it must be clearly stressed that despite being treated with cytostatic drugs for such a long time, the patient's treatment tolerance was very good, and there was no significant worsening in the quality of the patient's life, except for the last stage of the disease.
it must be noted that in the case of the described patient, apart from the survival time, disease progression occurred in similar time intervals. usually, in the case of long-term treatment of metastatic carcinoma, remission periods become shorter with time.
The disease stability and good response to treatment observed in this case are not typical of metastatic nPc (tab. 1). 
conclusIon
The question is what steps to take with very limited standard procedures, or in their absence. in europe, a disease is considered rare if it affects less than 5 persons per 10,000 [27] . in the case of diseases where it is difficult to obtain a large enough study group and conduct clinical trials, which could help to develop the most efficient standard procedures, attention should be paid to doctors demonstrating an individual approach to patients. an issue frequently discussed by medical practitioners, not only oncologists, is whether there is a justification for creating centres intended for the treatment of rare diseases. a disease, including nPc, may be rare in one region and common in another. Bearing the above in mind, it is sensible to bring a larger number of patients with a specific disease to one centre. it would allow for clinical studies to be conducted, procedure recommendations to be developed, clinical experiences to be exchanged between doctors, and specialist personnel to be trained [28] . 
